| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $22.3M | -1.8% | +43.3% |
| SG&A Expense | $7.7M | +13.1% | +26.4% |
| Operating Income | -$30.0M | -1.7% | -38.6% |
| Net Income | -$26.9M | -0.7% | -53.5% |
| EPS (Basic) | -$0.71 | +5.3% | -42.0% |
| EPS (Diluted) | -$0.71 | +5.3% | -42.0% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $251.4M | +356.5% | +539.4% |
| Short-term Investments | $261.7M | +27.4% | -7.0% |
| Current Assets | $520.7M | +92.7% | +59.7% |
| Total Assets | $535.3M | +87.5% | +61.7% |
| Current Liabilities | $14.3M | +20.5% | +101.7% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$62.8M | — | — |
| Capital Expenditures | $447K | — | — |
| Investing Cash Flow | -$13.1M | — | — |
| Financing Cash Flow | $270.5M | — | — |
| Free Cash Flow | -$63.2M | — | — |
| $23.7M |
| +7.8% |
| +195.2% |
| Stockholders' Equity | $511.6M | +94.2% | +58.3% |